

Bal Seal expands in China to tap into growing medical industry

24 April 2012 | News | By BioSpectrum Bureau

Bal Seal expands in China to tap into growing medical industry



Singapore: Responding to predicted growth in China's medical industry, Bal Seal Engineering, a leading provider of custom-engineered sealing, connecting, conducting and EMI shielding components, has added a new territory manager to its Asia Pacific sales team.

Michael Wong, a degreed mechanical engineer, joined Bal Seal earlier this summer as its third territory manager in the region. He is responsible for maintaining relationships with the company's existing customers in China, as well as cultivating new ones.

According to Joseph Mok, Managing Director of Bal Seal's Asia subsidiary, Wong's hiring was a direct response to an anticipated increase in demand for solutions to engineering challenges in China's flourishing medical industry.

"Medical manufacturing in this region is very strong," says Mok. "We're looking at a potential double-digit growth rate over the next year, and we want to have the resources in place to service this with skilled, dedicated coverage on a localized level. Now, with Michael's help, we're in an even better position to do that."

Along with the addition of Wong to its sales force in Asia, Mok says Bal Seal will exhibit at MEDTEC China for the first time in the event's seven-year history. At stand #1707 in Hall 4 of the Shanghai World Expo Exhibition & Convention Center, the company will be demonstrating its Bal Seal Canted Coil Spring® technology, which facilitates mechanical connecting,

electrical current-carrying, EMI shielding and fluidic seal energizing in a broad range of today's medical devices.

Mok added that the company's exhibit will feature the SYGNUS Implantable Contact System, the world's first integrated seal and electrical contact system for active implantable devices used in cardiac rhythm management, neuromodulation and sensing. SYGNUS is engineered to help large and small device OEMs accelerate the development process and dedicate valuable resources to therapy and function improvements, instead of component procurement and testing.